Literature DB >> 30849511

Revisiting the role of the innate immune complement system in ALS.

Sandra E Parker1, Angela M Hanton1, Stephen N Stefanou1, Peter G Noakes2, Trent M Woodruff3, John D Lee4.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal and rapidly progressing motor neuron disease without effective treatment. Although the precise mechanisms leading to ALS are yet to be determined, there is now increasing evidence implicating components of the innate immune complement system in the onset and progression of its motor phenotypes. This review will survey the clinical and experimental evidence for the role of the complement system in driving neuroinflammation and contributing to ALS disease progression. Specifically, it will explore findings regarding the different complement activation pathways involved in ALS, with a focus on the terminal pathway. It will also examine potential future research directions for complement in ALS, highlighting the targeting of specific molecular components of the system.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30849511     DOI: 10.1016/j.nbd.2019.03.003

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  10 in total

1.  TDP-43 knockdown causes innate immune activation via protein kinase R in astrocytes.

Authors:  Thomas J LaRocca; Andrea Mariani; Linda R Watkins; Christopher D Link
Journal:  Neurobiol Dis       Date:  2019-06-21       Impact factor: 5.996

2.  Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System.

Authors:  Anna Gaimari; Michele Fusaroli; Emanuel Raschi; Elisa Baldin; Luca Vignatelli; Francesco Nonino; Fabrizio De Ponti; Jessica Mandrioli; Elisabetta Poluzzi
Journal:  Drug Saf       Date:  2022-05-24       Impact factor: 5.606

Review 3.  The emerging role of complement in neuromuscular disorders.

Authors:  John D Lee; Trent M Woodruff
Journal:  Semin Immunopathol       Date:  2021-10-27       Impact factor: 9.623

Review 4.  The Complement System in the Central Nervous System: From Neurodevelopment to Neurodegeneration.

Authors:  Ying Chen; John Man Tak Chu; Raymond Chuen Chung Chang; Gordon Tin Chun Wong
Journal:  Biomolecules       Date:  2022-02-21

Review 5.  Are Circulating Cytokines Reliable Biomarkers for Amyotrophic Lateral Sclerosis?

Authors:  Laura Moreno-Martinez; Ana Cristina Calvo; María Jesús Muñoz; Rosario Osta
Journal:  Int J Mol Sci       Date:  2019-06-05       Impact factor: 5.923

6.  Crry silencing alleviates Alzheimer's disease injury by regulating neuroinflammatory cytokines and the complement system.

Authors:  Xi-Chen Zhu; Lu Liu; Wen-Zhuo Dai; Tao Ma
Journal:  Neural Regen Res       Date:  2022-08       Impact factor: 5.135

7.  Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.

Authors:  Peter Garred; Andrea J Tenner; Tom E Mollnes
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

8.  Amyotrophic lateral sclerosis and the innate immune system: protocol for establishing a biobank and statistical analysis plan.

Authors:  Anne-Lene Kjældgaard; Katrine Pilely; Karsten Skovgaard Olsen; Anne Øberg Lauritsen; Stephen Wørlich Pedersen; Kirsten Møller; Peter Garred
Journal:  BMJ Open       Date:  2020-08-05       Impact factor: 2.692

Review 9.  Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here?

Authors:  Khalil Mallah; Christine Couch; Davis M Borucki; Amer Toutonji; Mohammed Alshareef; Stephen Tomlinson
Journal:  Front Immunol       Date:  2020-09-10       Impact factor: 7.561

Review 10.  Tipping the balance: intricate roles of the complement system in disease and therapy.

Authors:  Richard B Pouw; Daniel Ricklin
Journal:  Semin Immunopathol       Date:  2021-10-26       Impact factor: 9.623

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.